79 Results
Sort By:
Published on December 31, 2019
Alex Trebek appeared well en route to surviving pancreatic cancer this past summer when his doctors followed up his initial successful chemotherapy with an undisclosed immunotherapy. That move backfired. “I was doing so well. And my numbers went down to the equivalent of a normal human being who does not…
Published on July 18, 2019
If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark (since acquired by Agilent Technologies) received authorization to market HercepTest. The immunohistochemistry (IHC) assay was designed to detect human epidermal growth factor receptor 2 (HER2) protein…
Published on March 30, 2019
David Bentley trained in medical genetics at Guy’s Hospital in London before spending 12 years at the Sanger Centre (now the Wellcome Trust Sanger Institute). There, as Head of Human Genetics and working with director Sir John Sulston and colleagues, he helped set up the British arm of the Human…
Published on March 12, 2019
Biocartis said today it will partner with Bristol-Myers Squibb (BMS) to develop a companion diagnostic for the pharma giant’s immuno-oncology therapies based on the Belgian molecular diagnostics developer’s Idylla MSI test. Under the collaboration—whose value and other financial details were not disclosed—Biocartis and BMS agreed to pursue joint development and…
Published on February 6, 2019
Foundation Medicine plans to provide comprehensive genomic profiling for eligible veterans living with advanced cancer under a five-year, $111.5 million contract awarded by the U.S. Department of Veterans Affairs. The contract, awarded under the Veterans Affairs National Precision Oncology Program (NPOP), encompasses all of Foundation Medicine’s available tests—including FoundationOne CDx…
Published on November 13, 2018
GenomOncology said today that its proprietary match algorithm and extensive Knowledge Management System (KMS) application programming interface (API) suite will be used by Indiana University (IU) School of Medicine to provide real-time clinical trial recommendations to clinical researchers treating IU patients, through a partnership whose value was not disclosed. GenomOncology said…
Published on June 20, 2018
Signaling growing interest in personalized oncology treatments as well as diagnostics, Roche plans a $2.4 billion acquisition that will expand its majority stake in Foundation Medicine into full ownership of the cancer-focused molecular diagnostics developer. Under the deal, Roche and Foundation Medicine said, they plan to combine their expertise in…
Published on March 26, 2018
Scientists report that they have found new genetic mutations that promote the survival of cancer cells. Their study also provided a clearer understanding of how some cancer cells are able to resist treatment. The findings (“Novel Putative Drivers Revealed by Targeted Exome Sequencing of Advanced Solid Tumors”) are published in PLOS ONE.…
Published on March 20, 2018
Cofactor Genomics said it will partner with the NIH’s National Cancer Institute and three unnamed academic and pharma institutions to demonstrate the clinical utility of the company’s Cofactor Paragon immune-profiling assay, through a collaboration whose value was not disclosed. The collaboration will focus on using Cofactor’s RNA-based immune profiling technology…
Published on February 27, 2018
The Broad Institute of MIT and Harvard and the Dana-Farber Cancer Institute have launched the Metastatic Prostate Cancer (MPC) Project, designed to encourage men with metastatic prostate cancer in the U.S. and Canada to share their data with researchers studying the disease. As of yesterday, when MPC was announced, 220…
Published on January 30, 2018
Foundation Medicine said today its comprehensive genomic profiling (CGP) assays will be used by the European Organisation for Research and Treatment of Cancer (EORTC) to inform patient eligibility for oncology clinical trials through EORTC's Screening Patients for Efficient Clinical Trial Access (SPECTA) program. Under an agreement whose value was not…
Published on November 8, 2017
Caris Life Sciences is accusing Foundation Medicine in a federal lawsuit of infringing on five Caris patents in the development of its cancer assays FoundationOne®, FoundationACT® and FoundationOne® Heme. “As a result of Defendant’s infringement and the threat of its continued infringement, Caris faces a substantial risk of irreparable harm,”…
Published on June 9, 2017
Foundation Medicine and Caris Life Sciences will alert physicians to patients who are eligible for the National Cancer Institute’s Phase II NCI-MATCH (Molecular Analysis for Therapy Choice) study, through separate collaborations announced this week. The companies said they will inform the physicians, who will work from more than 1,100 clinical…
Published on June 5, 2017
A partnership launched by Thermo Fisher Scientific with the Institute of Medical Genetics and Pathology at University Hospital Basel aims to accelerate clinical research into oncology and immuno-oncology by developing and validating next-generation sequencing (NGS)-based cancer diagnostics. The Institute is the first partner in Thermo Fisher Scientific’s Next Generation Sequencing…
Published on March 20, 2017
Development-stage biopharma company Loxo Oncology has begun a collaboration with Ventana Medical Systems to develop and commercialize a pan-TRK immunohistochemistry (IHC) test as a companion diagnostic to identify patients across tumor types suitable for treatment with larotrectinib. Loxo Oncology and Ventana, a member of the Roche Group of companies, will…